Trials / Terminated
TerminatedNCT00447122
BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer: A Phase I Study #108181
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Brown University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase I study of lapatinib and gemcitabine for patients with metastatic pancreaticobiliary cancer.
Detailed description
To evaluate the safety/tolerability and potential antitumor activity of lapatinib, at dose ranges of 1000 to 1500 mg/d, in combination with gemcitabine and gemcitabine/oxaliplatin (GEMOX) in patients with advanced pancreaticobiliary cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcitabine 1000mg/m2 30 minutes | 1000mg/m2 30 minutes |
| DRUG | Lapatinib 1000mg/d | 1000mg/d |
| DRUG | Lapatinib 1500mg/d | 1500mg/d |
| DRUG | Gemcitabine 1000mg/m2 100minutes | 1000mg/m2 100minutes |
| DRUG | Oxaliplatin 100mg/m2 | 100mg/m2 |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2008-08-01
- Completion
- 2008-08-01
- First posted
- 2007-03-14
- Last updated
- 2022-03-08
- Results posted
- 2014-05-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00447122. Inclusion in this directory is not an endorsement.